Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with or without topical nepafenac for treatment-naive diabetic macular edema
MOH_2021-04-21_009899Phase 4Not yet recruiting
- Sponsor
- ד"ר סאמר ח'טיב
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nepafenac and bevacizumab in diabetic macular edema (DME) (2 arms), sponsored by ד"ר סאמר ח'טיב. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
nepafenacbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2021-04-21_009899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-21_009899.